香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 授出日期 二零二五年十一月二十日（「授出日期」） MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2172） 授出購股權 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第17.06A條 而作出。 微創腦科學有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈，於二零二五年十一月二十日，本公司已決議根據本公 司於二零二三年七月十二日採納之股份計劃（「股份計劃」）向本集團腦機接口 技術研發資深總監及混沌腦機研究院首席研究員Will Zhang博士（「承授人」）授 出購股權（「購股權」），以合共認購最多500,000股本公司股本中每股面值0.00002 美元之本公司普通股（「股份」），惟須待承授人接納後，方可作實。Will Zhang ...

智通财经APP获悉，香港联交所最新资料显示，11月19日，微创脑科学(02172)股东将股票由国元证券经 纪转入中信证券经纪香港，转仓市值8.32亿港元，占比12.91%。 微创脑科学发布公告，常兆华博士(常博士)因需投放更多时间于其他业务而辞任非执行董事及董事会主 席。孙庆蔚先生(孙先生)因需投放更多时间于其他业务而辞任非执行董事。张劼博士(张博士)获委任为 非执行董事兼董事会主席。刘旭东先生(刘先生)获委任为非执行董事。 ...

微创脑科学发布公告，常兆华博士(常博士)因需投放更多时间于其他业务而辞任非执行董事及董事会主 席。孙庆蔚先生(孙先生)因需投放更多时间于其他业务而辞任非执行董事。张劼博士(张博士)获委任为 非执行董事兼董事会主席。刘旭东先生(刘先生)获委任为非执行董事。 智通财经APP获悉，香港联交所最新资料显示，11月19日，微创脑科学(02172)股东将股票由国元证券经 纪转入中信证券经纪香港，转仓市值8.32亿港元，占比12.91%。 ...

Core Viewpoint - MicroPort Scientific Corporation (02172) announced changes in its board of directors, with Dr. Chang Zhao Hua resigning as non-executive director and chairman of the board to focus on other business commitments, while Mr. Sun Qing Wei also resigned for similar reasons. Dr. Zhang Jie has been appointed as the new non-executive director and chairman of the board, and Mr. Liu Xu Dong has been appointed as a non-executive director [1] Group 1 - Dr. Chang Zhao Hua resigned from his position to allocate more time to other business activities [1] - Mr. Sun Qing Wei also resigned from his role for similar reasons [1] - Dr. Zhang Jie has been appointed as the new non-executive director and chairman of the board [1] Group 2 - Mr. Liu Xu Dong has been appointed as a non-executive director [1]

Core Viewpoint - Micron Brain Science (02172.HK) announced the resignation of Chang Zhaohua as non-executive director and chairman of the board due to the need to allocate more time to other business commitments [1] - Sun Qingwei also resigned as non-executive director for similar reasons [1] - Zhang Jie has been appointed as the new non-executive director and chairman of the board, while Liu Xudong has been appointed as a non-executive director [1] Summary by Categories - **Management Changes** - Chang Zhaohua resigned as non-executive director and chairman of the board [1] - Sun Qingwei resigned as non-executive director [1] - Zhang Jie appointed as non-executive director and chairman of the board [1] - Liu Xudong appointed as non-executive director [1]

MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2172） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 | 張劼博士 | （非執行董事兼董事會主席） | | --- | --- | | 謝志永先生 | （執行董事） | | 王亦群先生 | （執行董事） | | 劉旭東先生 | （非執行董事） | | 吳夏女士 | （非執行董事） | | 張海曉博士 | （獨立非執行董事） | | 樊欣先生 | （獨立非執行董事） | | 李志勇先生 | （獨立非執行董事） | 董事會設立三個委員會。下表提供各董事會成員於該等委員會中所擔任的職位。 | | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 張劼博士 | | | | | | ...

Core Viewpoint - MicroPort Scientific Corporation (02172) announced changes in its board of directors, with Dr. Chang Zhao Hua resigning as non-executive director and chairman to focus on other business commitments, while Mr. Sun Qing Wei also resigned for similar reasons. Dr. Zhang Jie has been appointed as the new non-executive director and chairman, and Mr. Liu Xu Dong has been appointed as a non-executive director [1] Group 1 - Dr. Chang Zhao Hua resigned from his position as non-executive director and chairman of the board [1] - Mr. Sun Qing Wei also resigned from his role as non-executive director [1] - Dr. Zhang Jie has been appointed as the new non-executive director and chairman of the board [1] Group 2 - Mr. Liu Xu Dong has been appointed as a non-executive director [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃由微創腦科學有限公司（「本公司」）根據香港聯合交易所有限公司（「聯 交所」）證券上市規則（「上市規則」）第13.51(2)條而作出。 本公司董事（「董事」）會（「董事會」）宣佈，以下董事會變動自二零二五年十一 月十四日起生效： 非執行董事及董事會主席辭任 常兆華博士（「常博士」）因需投放更多時間於其他業務而辭任非執行董事及董 事會主席。孫慶蔚先生（「孫先生」）因需投放更多時間於其他業務而辭任非執 行董事。常博士及孫先生已向本公司確認，彼等與董事會概無意見分歧。本公 司確認，概無有關常博士及孫先生辭任之事宜須敦請本公司股東垂注。本公司 謹此感謝常博士及孫先生在擔任非執行董事期間對本集團所作之努力及寶貴 貢獻，並期待彼等日後就本集團發展持續提供專業指導、建議及意見。 MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 ...

Core Viewpoint - The brain-computer interface (BCI) concept stocks in the Hong Kong market have shown strong performance, driven by the advancement of a domestically developed implantable wireless BCI system entering a special review process by the National Medical Products Administration (NMPA) in China, marking a significant step in the commercialization of this technology [1][2]. Group 1: Market Performance - Brain动极光-B has increased by over 9%, with a latest price of 6.960 and a total market capitalization of 8.813 billion [2] - 微创脑科学 has risen by over 4%, with a latest price of 11.880 and a total market capitalization of 6.843 billion [2] - 南京熊猫电子股份 has gained nearly 3%, with a latest price of 5.140 and a total market capitalization of 4.697 billion [2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive BCI product to enter the "green channel" for innovative medical devices in China, indicating a key transition from clinical validation to market access in this cutting-edge technology field [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing a significant rise, driven by advancements in technology and supportive regulatory developments in China [1] Group 1: Market Performance - Brain-machine concept stocks have collectively surged, with notable increases: Brainhole Aurora (06681) up 8.49% to HKD 6.9, Nanjing Panda Electronics (00553) up 3.2% to HKD 5.16, and Microneuroscience (02172) up 4.39% to HKD 11.9 [1] Group 2: Regulatory Developments - On November 11, Shanghai Ladder Medical Technology Co., Ltd.'s "implantable wireless brain-machine interface system" entered the special review process for innovative medical devices by the National Medical Products Administration (NMPA), marking it as the first invasive brain-machine interface product to enter this "green channel" in China [1] - The NMPA has also released the YY/T 1987—2025 standard for medical devices utilizing brain-machine interface technology, indicating a formalization of industry standards [1] Group 3: Industry Outlook - Dongwu Securities expresses optimism regarding the domestic policy support and accelerated clinical and commercial progress in the brain-machine interface industry [1] - Huafu Securities notes that advancements in brain science, artificial intelligence, medicine, cognitive neuroscience, and psychology are enriching the scope of brain-machine interfaces, highlighting multiple advantages for the development of this industry in China [1]